This is the authors' abstract. We don't add key points for this paper.
Accurate risk stratification is essential to prevent over- and undertreatment in newly diagnosed prostate cancer (PCa). In a pilot study with 49 men (36 PCa patients, 13 controls), we integrated non-invasive data modalities collected in a real-world clinical setting: radiomics from multiparametric magnetic resonance imaging (T2/ADC index-lesion features), routine and extended serological parameters, multimodal liquid biopsy features (copy number variations, chromosomal instability, methylation, fragmentation in plasma/urinary cfDNA), plus clinical and lifestyle factors. Pairwise Spearman analyses revealed significant inter-modality correlations. Our holistic PCa characterization showed that imaging phenotypes reflect tumor stage and molecular aggressiveness: lower ADC metrics correlated inversely with genomic cfDNA features, while ADC/T2 lesion volumes correlated positively with molecular signals. These results indicate that routine imaging and serological data may capture systemic tumor biology. Our proof-of-concept demonstrates feasibility of combining multiple data modalities in real-world clinical workflows and supports developing integrative models for non-invasive PCa risk stratification.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Riediger et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: